Revance Therapeutics is a biotechnology company focused on developing and commercializing innovative products for aesthetic and therapeutic applications. The company's lead product, DaxibotulinumtoxinA for Injection, is a novel botulinum toxin that has the potential to be a best-in-class product for the treatment of glabellar lines and other aesthetic and therapeutic indications. Revance Therapeutics was founded in 2002 and is headquartered in Newark, California.